Drug Profile
Typhoid vaccine Vi polysaccharide - Sanofi
Alternative Names: SP093; Typhim ViLatest Information Update: 08 Apr 2022
Price :
$50
*
At a glance
- Originator sanofi pasteur
- Developer Sanofi
- Class Antibacterials; Bacterial vaccines; Polysaccharides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Typhoid
Most Recent Events
- 01 Jan 2013 Launched prior to 2013 for Typhoid (prevention) in Canada (IM)
- 01 Jan 2013 Launched prior to 2013 for Typhoid (prevention) in Israel (IM)
- 01 Dec 2012 Launched prior to 2013 for Typhoid (prevention) in South Africa (IM)